1. Home
  2. AGEN vs CMT Comparison

AGEN vs CMT Comparison

Compare AGEN & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • CMT
  • Stock Information
  • Founded
  • AGEN 1994
  • CMT 1996
  • Country
  • AGEN United States
  • CMT United States
  • Employees
  • AGEN N/A
  • CMT N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • CMT Electronic Components
  • Sector
  • AGEN Health Care
  • CMT Consumer Discretionary
  • Exchange
  • AGEN Nasdaq
  • CMT Nasdaq
  • Market Cap
  • AGEN 142.8M
  • CMT 166.5M
  • IPO Year
  • AGEN 2000
  • CMT N/A
  • Fundamental
  • Price
  • AGEN $4.55
  • CMT $21.92
  • Analyst Decision
  • AGEN Buy
  • CMT
  • Analyst Count
  • AGEN 2
  • CMT 0
  • Target Price
  • AGEN $14.50
  • CMT N/A
  • AVG Volume (30 Days)
  • AGEN 395.5K
  • CMT 39.3K
  • Earning Date
  • AGEN 11-11-2025
  • CMT 11-04-2025
  • Dividend Yield
  • AGEN N/A
  • CMT N/A
  • EPS Growth
  • AGEN N/A
  • CMT N/A
  • EPS
  • AGEN N/A
  • CMT 1.08
  • Revenue
  • AGEN $101,706,000.00
  • CMT $276,176,000.00
  • Revenue This Year
  • AGEN $60.49
  • CMT N/A
  • Revenue Next Year
  • AGEN N/A
  • CMT $6.42
  • P/E Ratio
  • AGEN N/A
  • CMT $20.44
  • Revenue Growth
  • AGEN N/A
  • CMT N/A
  • 52 Week Low
  • AGEN $1.38
  • CMT $12.25
  • 52 Week High
  • AGEN $7.34
  • CMT $22.00
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 48.05
  • CMT 72.32
  • Support Level
  • AGEN $4.36
  • CMT $20.96
  • Resistance Level
  • AGEN $5.20
  • CMT $22.00
  • Average True Range (ATR)
  • AGEN 0.27
  • CMT 0.77
  • MACD
  • AGEN 0.04
  • CMT 0.14
  • Stochastic Oscillator
  • AGEN 40.91
  • CMT 97.62

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About CMT Core Molding Technologies Inc

Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.

Share on Social Networks: